Thomson Reuters/Verus upgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a sell rating to a hold rating in a report issued on Monday, StockRatingsNetwork.com reports.
ARIA has been the subject of a number of other recent research reports. Analysts at UBS AG cut their price target on shares of Ariad Pharmaceuticals from $5.50 to $2.50 in a research note to investors on Wednesday, November 13th. They now have a neutral rating on the stock. Separately, analysts at Goldman Sachs Group Inc. reiterated a neutral rating on shares of Ariad Pharmaceuticals in a research note to investors on Tuesday, November 12th. Finally, analysts at Credit Suisse cut their price target on shares of Ariad Pharmaceuticals from $4.00 to $2.50 in a research note to investors on Friday, November 1st. They now have a neutral rating on the stock. Two investment analysts have rated the stock with a sell rating, twenty-two have given a hold rating and one has issued a buy rating to the company’s stock. Ariad Pharmaceuticals has a consensus rating of Hold and an average target price of $8.30.
Ariad Pharmaceuticals (NASDAQ:ARIA) traded up 4.27% on Monday, hitting $5.35. 32,203,744 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a one year low of $2.15 and a one year high of $24.59. The stock has a 50-day moving average of $4.44 and a 200-day moving average of $15.11. The company’s market cap is $993.3 million.
Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.43) by $0.07. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.67 million. During the same quarter last year, the company posted ($0.32) earnings per share. Ariad Pharmaceuticals’s revenue was up 1864.7% compared to the same quarter last year. On average, analysts predict that Ariad Pharmaceuticals will post $-1.56 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.